Concinnity Genetics builds AI‑driven, RNA‑based control systems that can be integrated into gene and cell therapies to modulate therapeutic activity on demand. Their platform designs custom regulatory circuits that enable reversible activation, repression, or self‑limiting expression, helping biopharma developers improve safety, dose flexibility, and the therapeutic window of their products.
Funding
$3.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
2OEFounders
Product
Problem
Gene and cell therapies often cause safety concerns due to uncontrolled gene expression and unpredictable side effects, limiting their clinical adoption and the range of treatable diseases.
Solution
Concinnity Genetics provides RNA‑based control mechanisms that can be integrated into gene and cell therapies to modulate activity after dosing. Their AI‑driven design platform leverages synthetic biology to create bespoke regulatory circuits that respond to cellular cues, allowing precise on‑demand activation or deactivation of therapeutic genes. By embedding these control systems, developers can mitigate adverse events, improve dose flexibility, and expand the therapeutic window of their products. Concinnity partners with biopharma companies to design, validate, and implement these safety layers throughout the development pipeline.
Target Audience
Primary customers are biopharmaceutical companies and academic groups developing gene or cell therapies that require enhanced safety controls.
Features
- AI‑assisted design of custom RNA regulatory elements tailored to specific therapeutic targets
- Modular control circuits that enable reversible activation, repression, or self‑limiting expression of gene therapies
- In‑silico and wet‑lab validation workflows to assess efficacy, specificity, and off‑target risk
- Compatibility with a broad range of viral vectors and cell‑based delivery platforms
- Partnership models offering co‑development, licensing, or bespoke engineering services